A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R

Ahn-Gook Pharmaceuticals

Status and phase: Not yet enrolling; Phase 3

Conditions: Hypercholesterolemia

Treatments: Drug: AG2304R; Drug: AG2304T

Study type: Interventional

Funder types: Industry

Identifiers

NCT06717360

AG2304 P3

Details and patient eligibility

About

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R in Patients with Primary Hypercholesterolemia

Enrollment: 140 estimated patients

Sex: All

Ages: 19 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults aged 19-80
• Patients with primary hypercholesterolemia
• Those who voluntarily written consent to participate in this clinical trial

Exclusion criteria

• The subject not meet the specified LDL-C level
• Other exclusions applied

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

140 participants in 2 patient groups

AG2304T

Experimental group

Treatment:

Drug: AG2304T

AG2304R

Active Comparator group

Treatment:

Drug: AG2304R